Vasculitis

The American College of Rheumatology and the Vasculitis Foundation have issued joint guidelines for the management of various types of vasculitis.

Researchers outline the impact of COVID-19 in a cohort of Italian patients with large-vessel vasculitis.

Treatment with the interleukin 6 inhibitor tocilizumab over 96 weeks is associated with a reduction in glucocorticoid dose among patients with Takayasu arteritis, researchers report.

EULAR has released updated recommendations for the management of large vessel vasculitis, including giant cell arteritis and Takayasu arteritis.

Jung JY et al. Pediatr Rheumatol 2018; 16: 79. doi: 10.1186/s12969-018-0296-z

Keser G, Aksu K. Rheumatol Int 2018. doi: 10.1007/s00296-018-4157-3

The authors report a young female who presented with acute pulmonary edema due to aortic regurgitation without any other clinical features of Takayasu arteritis, subsequently diagnosed as Takayasu arteritis after a long follow up period.

de Silva NL et al. BMC Rheumatol 2018; 2: 20. doi: 10.1186/s41927-018-0028-5

Novikov P et al. Rheumatology (Oxford) 2018. doi: 10.1093/rheumatology/key197

Kwon OC et al. Arthritis Res Ther 2018; 20: 142. doi: 10.1186/s13075-018-1643-7

Tombetti E, Mason JC. Rheumatology (Oxford) 2018; Advance online publication. doi: 10.1093/rheumatology/key040

Genga E, Oyoo O, Adebajo A. Curr Rheumatol Rep 2018; 20: 4. doi: 10.1007/s11926-018-0711-y

Mavrogeni SI et al. Rheumatol Int 2018; Advance online publication. doi: 10.1007/s00296-018-4004-6

The authors present a case of 21-year-old Mexican woman of Mestizo descent with chronic hypertension diagnosed since she was 15-years old who presented severe hypertension during pregnancy (early second trimester).

Lumbreras-Marquez J et al. J Med Case Reports 2018; 12: 12. doi: 10.1186/s13256-017-1534-6

Kellett et al. summarize the recent literature on the pathogenesis, management, and outcome of small-, medium-, and large-vessel renal vasculitis in the pediatric population.

Kellett S, Jawa N, Noone D. Curr Pediatr Rep 2017;5:87-99. doi:10.1007/s40124-017-0138-3

This review focuses on the considerable recent therapeutic advances for the treatment of vasculitis, including the development of outcome measures facilitating clinical trial design.

Eleftheriou D & Brogan PA. Pediatr Rheumatol 2016;14:26. doi:10.1186/s12969-016-0082-8

The authors of this research propose that the diagnostic performance of EULAR/PRINTO/PRES classification criteria had higher sensitivity and specificity than the ACR criteria in adult IgA vasculitis. 

Blockmans D. Curr Treat Options in Rheum 2016;2:153–160. doi:10.1007/s40674-016-0044-9